HERTFORDSHIRE, England and PITTSBURGH , and NEWARK, Calif. , Feb. 28, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX
HERTFORDSHIRE, England and PITTSBURGH , Feb. 28, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its CFO, Ken Parks , will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Fla. , on Monday, Mar. 5, 2018 , at 1:40 p.m. ET .
HERTFORDSHIRE, England and PITTSBURGH , Feb. 28, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that its CEO, Heather Bresch , will present at the Barclays Global Healthcare Conference in Miami Beach, Fla. , on Wednesday, Mar. 14, 2018 , at 3:20 p.m. ET .
U.S. Patent Trial and Appeal Board denies St. Regis Mohawk Tribe's motion to terminate Restasis patent challenge Decision finds that Tribal sovereign immunity does not apply to inter partes review proceedings Federal District Court previously held patents invalid HERTFORDSHIRE, England
Mylan Board Nominates Pauline van der Meer Mohr for Election to Board of Directors HERTFORDSHIRE, England and PITTSBURGH , Feb. 26, 2018 /PRNewswire/ -- The Mylan N.V. (NASDAQ: MYL) Board of Directors today announced that non-executive Director Wendy Cameron will retire from the Board after more
- DTG/FTC/TAF is comprised of Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg - - Mylan's DTG/FTC/TAF will be the first TAF-based fixed-dose combination to be offered to patients in developing countries being treated for HIV - HERTFORDSHIRE, England
HERTFORDSHIRE, England , and PITTSBURGH , Feb. 8, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will release its fourth quarter and full year 2017 financial results, as well as its 2018 financial guidance, on Wednesday, Feb. 28 , following the close of the U.S.